← Human Trials & Peer-Reviewed Studies
The Effect of Liraglutide on Pancreatic Hormones and Its Size
Plain-language guide to NCT03520062: not phased interventional trial of Liraglutide, 14 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT03520062
- Phase
- not phased
- Status
- completed
- Start
- 2017-08-15
- Completion (planned or actual)
- 2019-04-30
- Participants
- 14 (actual)
- Design
- na, open label (everyone knows who gets what), basic_science
- Conditions studied
- Obesity
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered not phased trial tested Liraglutide.
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone used to treat type 2 diabetes and severe overweight (Liraglutide).The two pancreas enzymes: amylase and lipase are slightly elevated in GLP-1 treated compared with placebo-treated individuals.
It had 1 arm (groups): GLP-1 Receptor Agonist (Liraglutide) (experimental).
The registry classes the interventions as drug.
Who Took Part
14 actual participants took part.
It was open to men only aged from 18 years up to 65 years.
Healthy volunteers could join, not only people with the condition.
Examples of who could join: BMI ≥ 26 og \< 50 kg/m2.
The full record lists 1 inclusion and 1 exclusion criteria.
How the Study Was Run
It was run as a single-group and open-label study.
Nothing was hidden in this open-label Liraglutide study: the participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2017-08-15 with completion listed for 2019-04-30.
It ran at 1 site in Denmark.
Its stated primary purpose is basic science.
What Was Measured
Researchers chose this as the main measure: Volumetric Changes of the Pancreas (time frame: 6 weeks).
It also tracked 7 secondary outcomes, for example Changes in Plasma Concentrations of Pancreatic Amylase and Lipase, Changes in body weight, Changes in glycemic index, Plasma concentrations of glucagon, insulin and citrullin, Plasma concentrations of the drug and Other MR based changes in the pancreas (edema, cellularity and structural changes).
What This Means in Plain Language
Put simply, this is a not phased trial of Liraglutide in 14 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Liraglutide compound page, all human trials.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.